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Abstract
 
Inflammation likely has a role in the early genesis of certain malignancies. Interleukin (IL)-15, a
proinflammatory cytokine and growth factor, is required for lymphocyte homeostasis. Intrigu-
ingly, the expression of IL-15 protein is tightly controlled by multiple posttranscriptional
mechanisms. Here, we engineered a transgenic mouse to overexpress IL-15 by eliminating
these posttranscriptional checkpoints. IL-15 transgenic mice have early expansions in natural
killer (NK) and CD8
 
1
 
 T lymphocytes. Later, these mice develop fatal lymphocytic leukemia
with a T-NK phenotype. These data provide novel evidence that leukemia, like certain other
cancers, can arise as the result of chronic stimulation by a proinflammatory cytokine.
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Introduction
 
IL-15 is a pleiotropic cytokine that is important for both
innate and adaptive immune cell homeostasis, as well as pe-
ripheral immune function (1). IL-15 shares the common 
 
g
 
chain (
 
g
 
c
 
) and IL-2/15R
 
b
 
 with IL-2 for signaling, but also
utilizes a private IL-15R
 
a
 
 subunit for high affinity binding
(2–4). Numerous in vitro and in vivo studies have docu-
mented a critical role for IL-15 in the development, sur-
vival, and function of the NK cell lineage (5–12). Further,
IL-15 is required for the normal expansion and/or survival
of nonclassical T cells and memory phenotype TCR-
 
a
 
/
 
b
 
CD8
 
1
 
 T cells, while not being essential for their develop-
ment (11–13). Additional studies have documented a role
for IL-15 in peripheral immune functions such as T lym-
phocyte trafficking (14), innate immune IFN-
 
g
 
 production
(15), and host defense against infectious pathogens (1).
These studies are consistent with the broad expression of
IL-15 and IL-15R
 
a
 
 by multiple cell types and tissues, sug-
gesting that this ligand/receptor may mediate a wide range
of functions in vivo (2, 4). Indeed, the phenotypes of mice
deficient in IL-15/IL-15R
 
a
 
 (11, 12), compared with mice
deficient in IL-2/IL-2R
 
a
 
 (16–18), definitively demon-
strate a large variety of unique in vivo functions mediated
by IL-15 (19).
Despite an abundance of transcript in multiple tissues and
cell types, IL-15 is poorly translated and secreted. Three
primary posttranscriptional checkpoints are responsible for
this observation: multiple AUGs in the 5
 
9
 
 UTR (2, 20), in-
efficient long signal peptides (LSPs) and short signal pep-
tides (SSPs; references 21 and 22), and a negative regulator
near the COOH terminus of the precursor proteins (22).
Through the systematic elimination of these three check-
points, the synthesis of bioactive human IL-15 protein in-
creased 250-fold in vitro (23). Such tight posttranscrip-
tional control of the IL-15 gene product is unusual for
most cytokines thus far characterized, suggesting that con-
stitutively abundant IL-15 protein may somehow be dele-
terious to the host.
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Fatal Leukemia Follows Lymphocyte Expansion in IL-15 Transgenic Mice
 
Recently, a connection between chronic inflammatory
processes and the genesis of cancer has been appreciated
(24). Inflammation resulting from persistent infections has
been linked to malignancies, including 
 
Helicobacter pylori
 
 and
gastric carcinoma, schistosomiasis, and bladder cancer, as
well as hepatitis C virus and hepatocellular carcinoma (24).
The increased production of macrophage migration inhibi-
tory factor (MIF) during 
 
H. pylori
 
 infection, a molecule that
downregulates the p53 tumor suppressor gene during in-
flammation, provided one direct mechanism whereby the
proinflammatory state may result in susceptibility to trans-
forming genetic mutation (25). Further, individuals with
polymorphisms at the IL-1
 
b
 
 gene, resulting in increased ex-
pression of proinflammatory IL-1
 
b
 
 during 
 
H. pylori
 
 infec-
tion, have a higher risk of developing gastric cancers (26).
Leukemia is a complex, heterogeneous disorder with
multiple molecular etiologies (27). However, direct evi-
dence that mediators of inflammation can, via alterations in
proliferation or survival, contribute to leukemogenesis is
lacking. We hypothesized that deregulation of IL-15 gene
expression, resulting in alterations in lymphocyte homeo-
stasis, could promote malignant transformation in lympho-
cytes. In the current report, we tested these hypotheses in
vivo by engineering transgenic mice that lack posttranscrip-
tional control of IL-15 gene expression, thereby efficiently
translating and secreting murine IL-15 protein. These IL-
15 transgenic (IL-15tg)
 
1
 
 mice have early expansions of pe-
ripheral blood lymphocytes, specifically NK cells and
memory phenotype CD8
 
1
 
 T cells. Later, IL-15tg mice de-
velop a striking leukemic expansion, some composed pri-
marily of clonal CD3
 
1
 
TCR-
 
a
 
/
 
b
 
1
 
 T cells, along with pro-
gressive alopecia, multiorgan lymphocytic infiltrates, and
premature death, not unlike the leukemia of large granular
lymphocytes that occurs in patients (28).
 
Materials and Methods
 
Reagents.
 
The following mAbs reactive with murine cells
were purchased from BD PharMingen: CD2 (RM2-5), CD3
(145-2C11), CD4 (RM4-5), CD5 (53-7.3), CD8a (53-6.7),
CD8b2 (53-5.8), CD19 (1D3), CD25 (7D4), CD44 (IM7),
CD69 (H1.2F3), CD122 (TM-
 
b
 
1), CD62L (MEL-14), Ly6C
(AL-21), DX5 (DX5), NK1.1 (PK136), Ly49D (4E5), B220
(RA3-6B2), Mac-1 (M1/70), TCR-
 
b
 
 (H57-597), TCR-
 
g
 
/
 
d
 
(GL3), V
 
b
 
2 (B20.6), V
 
b
 
11 (RR3-15), and IFN-
 
g
 
 (XMG1.2),
and used as direct conjugates to PE, FITC, or peridinin chloro-
phyll protein (PerCP). The following mAb were purchased from
BD PharMingen and used as isotype controls: hamster IgG
(G235-2356), mouse IgG2b/k (49.2), rat IgG2a/k (R35-95), rat
IgG2b/k (A95-1), and rat IgM/k (R4-22), and used as direct con-
jugates to PE, FITC, or PerCP. For immunohistochemical analy-
sis, CD3 (145-2C11) mAb and anti–hamster IgG horseradish
peroxidase–conjugated secondary reagents were used (BD
PharMingen). For Western analysis the anti–FLAG M2 and M5
(Sigma-Aldrich) and probe 8 (Santa Cruz Biotechnology, Inc.)
Abs were used. The following cytokines were provided: recombi-
 
nant murine (rm)IL-15 (Immunex), recombinant human (rh)IL-2
(Hoffman LaRoche), and rmIL-12 (Genetics Institute).
 
IL-15 Transgene Design and Construction.
 
The IL-15 transgene
was designed to eliminate posttranscriptional checkpoints thereby
optimizing for the overexpression of an efficiently translated and
secreted murine IL-15 mature protein (see Fig. 1). The transgene
was cloned using standard DNA cloning techniques as follows.
The murine mIL-2 signal peptide coding sequence (nucleotides
49–108; sequence data are available from GenBank/EMBL/
DDBJ under accession no. K02292) was amplified from the
pmut-1 plasmid (American Type Culture Collection) with for-
ward primer (5
 
9
 
-GGCATGTACAGCATGCAGCTCG-3
 
9
 
) and
a reverse primer engineered with a NarI restriction site (under-
lined) (5
 
9
 
-ATCGGCGCCTGCGCTGTTGACAAGGAGCAC-
3
 
9
 
). The murine IL-15 cDNA encoding the mature protein (nu-
cleotides 610–951; sequence data are available from GenBank/
EMBL/DDBJ under accession no. U14332) was PCR amplified
from a full-length mIL-15 cDNA with a forward primer engi-
neered with a NarI restriction site (5
 
9
 
-GATGGCGCCAACTG-
GATAGATGTAAGATATG-3
 
9
 
) and a reverse primer (5
 
9
 
-
GATCGGATCCCTA
 
TTTGTCATCGTCGTCCTTGTA-
GTC
 
GGACGTGTTGATGAA-3
 
9
 
) engineered with a BamHI
restriction site (underlined) and FLAG epitope tag (italics). Both
PCR products were TA cloned into the PCR2.1 vector (Invitro-
gen) and accuracy confirmed by sequencing (ABI 377XL se-
quencer). The mIL-2SP coding sequence was subcloned into
pBluescript II SK (Stratagene) using an EcoRI site. Next, the
NarI/BamHI fragment of mIL-15 mature protein sequence was
ligated into this construct. The NarI restriction sites used to ligate
the mIL-2SP and mIL-15 mature protein ensured maintenance of
the proper open reading frame. We next ligated out of frame the
BamHI/NotI fragment of the human growth hormone (hGH)
gene (29) into the IL-2SP/IL-15 construct, downstream of the
IL-15 cDNA. Then the XhoI/HindIII fragment of mouse MHC
class I promoter (D
 
d
 
; references 30 and 31) from pGEM4z-2.7
was ligated into the multiple cloning site of pGEM7zf (Promega).
Finally, the resultant XhoI/SalI fragment of D
 
d
 
 promoter was li-
gated into the construct, upstream of the IL-2 signal peptide, re-
sulting in the final transgenic construct. A sequential digest of the
construct with XhoI and NotI, which releases the linearized 5.2-
kb transgene from pBluescript, was used for microinjections.
 
Generation of IL-15tg Mice.
 
The microinjection fragment was
isolated from the vector in a Tris-acetic acid-EDTA (TAE)-buf-
fered 1% agarose gel slice. DNA was purified from the agarose us-
ing the Qiaex II purification kit (QIAGEN) and eluted in an in-
jection buffer consisting of 10 mM Tris-HCl pH 7.4 and 0.1 mM
EDTA. An aliquot of the 5.2-kb microinjection fragment was
used to determine the DNA concentration by direct comparison
with the High DNA Mass Ladder (Life Technologies) on an
ethidium bromide–stained gel. DNA was injected into a single
pronucleus of FVB/N embryos (32) at a concentration of 2 ng/
 
m
 
l. Injected embryos were transferred to the oviducts of
pseudopregnant ICR foster mice. Potential transgenic mice were
screened by isolating genomic DNA (33) from tail biopsies and
testing for transgenic sequences by Southern hybridization (see
below).
 
Southern Analysis.
 
High molecular weight mouse DNA was
isolated from diced tail clips using a proteinase K, phenol/chloro-
form extraction as described (34). For Southern analysis, 10 
 
m
 
g of
genomic DNA was digested to completion with SstI and frac-
tionated on a 1% agarose gel followed by alkaline transfer to a
positively charged nylon membrane. DNA blots were hybridized
with a 
 
32
 
P-labeled 600-bp probe directed against hGH sequence
 
1
 
Abbreviations used in this paper: 
 
hGH, human growth hormone; IL-15tg, IL-
15 transgenic; LGL, large granular lymphocytic; RT, reverse transcription. 
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found in the transgene (see Fig. 1) and analyzed using a Storm
860 PhosphorImager and ImageQuant software (Molecular Dy-
namics). The expected size of SstI-digested transgene band is 2.6
kb, the unit length fragment obtained from multicopy tandem
transgene insertion.
 
Real Time Quantitative Reverse Transcription PCR.
 
Mouse tis-
sues were snap-frozen before RNA isolation and reverse tran-
scription (RT) as described (15). IL-15 transgene mRNA tran-
scripts were quantified by the dual-labeled fluorogenic probe
method, using a Prism 7700 thermal cycler and sequence detector
(PerkinElmer/ABI). Primers used were: IL-15 transgene forward,
5
 
9
 
-CGACGATGACAAATAGGGATCC-3
 
9
 
, reverse, 5
 
9
 
-
GACGTCCGGGAGCCTGTA-3
 
9
 
, probe, 5
 
9
 
-FAM AACTC-
CCCGAACCACTCAGGGTCCT TAMRA-3
 
9
 
; 18S rRNA
forward, 5
 
9
 
-CGGCTACCACATCCAAGGAA-3
 
9
 
, reverse, 5
 
9
 
-
GCTGGAATTACCGCGGCT-3
 
9
 
, probe, 5
 
9
 
-VIC TGCTG-
GCACCAGACTTGCCCTC TAMRA-3
 
9
 
. In parallel with ex-
perimental samples, standard curves for the IL-15 transgene and
18S rRNA (reference control) of known concentration were
quantitated, and absolute copy numbers were calculated. Final
quantitation is reported as the absolute copy number of IL-15
transgene transcripts per 10
 
6
 
 18S rRNA copies.
 
Western Blot Analysis.
 
Splenocyte lysates were loaded directly
onto 8–16% gradient gels (Tris-HCL; Bio-Rad Laboratories).
Recombinant FLAG protein was used as a positive control
(Sigma-Aldrich). Proteins were electrophoresed under denaturing
conditions and electroblotted to nitrocellulose membranes at 100 V
for 1 h at 4
 
8
 
C. Membranes were blocked overnight with 5% non-
fat dry milk in TBS plus 0.5% Tween 20 (TBST) and then incu-
bated for 1.5 h with rabbit anti-FLAG Ab (Santa Cruz Biotech-
nology, Inc.) diluted 1:400 in TBST plus 2% nonfat dry milk.
Membranes were washed with TBST and incubated for 1 h with
horseradish peroxidase–conjugated donkey anti–rabbit IgG (Am-
ersham Pharmacia Biotech) secondary Ab diluted 1:3,000 in
TBST. Proteins were detected using enhanced chemilumines-
cence reagents (ECL Plus and ECL hyperfilm; Amersham Phar-
macia Biotech).
 
Murine IL-15 ELISA.
 
96-well plates were coated with solu-
ble murine IL-15R
 
a
 
 as a primary capture reagent (35). Poly-
clonal rabbit anti–mouse IL-15 antiserum (15) was used as a sec-
ondary detection reagent (Immunex). rmIL-15 (Immunex) was
serially diluted for the standard curve, and the assay sensitivity was
between 9 and 40 pg/ml.
 
Tissues and Blood.
 
For autopsy, mice were anesthetized,
killed by cervical dislocation, and weighed. Peritoneal lavage was
performed with 10 ml ice cold PBS. Tissues were removed, ex-
amined grossly, and processed for RNA or protein isolation (snap
frozen in LN
 
2
 
), histology (fixed in 10% neutral buffered forma-
lin), and immunohistochemistry (frozen in OCT medium). Body
weight and selected organ weights were determined, and relative
body weight ratios were calculated. Spleen, thymus, and lymph
nodes were disrupted, RBC lysed, and strained through 70-
 
m
 
m
nylon mesh to obtain single cell leukocyte suspensions. Liver leu-
kocytes were isolated after collagenase digestion of liver homoge-
nate and density centrifugation over Lympholyte M (Cedarlane).
Bone marrow mononuclear cells were isolated from two femurs
by flushing with ice cold PBS. Peripheral blood was harvested
from the tail or retro-orbital plexus, and blood smears were pre-
pared. Whole blood was RBC lysed and all leukocyte suspensions
were enumerated electronically (Z1 cell counter; Coulter) and
manually (hemacytometer) in a blinded fashion.
 
Histopathology.
 
Fixed tissues were dehydrated with ethanol,
transferred to xylene, and embedded in paraffin using standard
 
histology techniques, and 3-
 
m
 
m sections were cut and stained
with hematoxylin and eosin. Peripheral blood smears were fixed
in ethanol and Wright/Giemsa stained. All histology samples
were reviewed by a pathologist (J. Durbin).
 
Analysis of NK Cell Function.
 
Fresh peripheral blood leuko-
cytes were used as effectors, and YAC-1 tumor cells as targets, in
a standard 
 
51
 
Cr release assay. For NK cell IFN-
 
g
 
 production, mu-
rine leukocytes were costimulated with IL-12 (10 ng/ml) and IL-
15 (1 ng/ml) for 48 h, and cell culture supernatants were then
harvested and assayed for IFN-
 
g
 
 protein by ELISA (15).
 
Flow Cytometry.
 
Staining of leukocyte suspensions with fluo-
rochrome-conjugated mAb reacting with cell surface antigens
and intracellular IFN-
 
g
 
 was performed as described (36). Forward
scatter, side scatter, and fluorescence data were collected on a
Coulter XL flow cytometer (Beckman Coulter) and analyzed
with the WinMDI software program (Joseph Trotter, Scripps
Research Institute, La Jolla, CA). Nonreactive isotype control
staining of identical cells was used to set quadrant gates with
 
$
 
99% of cells located in the negative quadrant. In flow cytomet-
ric histograms, fluorescence data is shown with tic marks in log
 
10
 
increments.
 
DNA PCR Assessment of TCR-
 
b
 
 Clonality.
 
D
 
b
 
 to J
 
b
 
 rear-
rangements were analyzed in high molecular weight genomic
DNA isolated from fresh peripheral mouse leukocytes using a
proteinase K, phenol/chloroform extraction as described (34).
PCR reactions (50 
 
m
 
l) contained 100 ng genomic DNA tem-
plate, 3 pmol of each primer, 0.2 mM of each dNTP, 2 mM
MgCl
 
2
 
, and 1 U Taq DNA polymerase in 1X PCR buffer as sup-
plied (PerkinElmer). Reactions were run on a 9700 thermocycler
(PerkinElmer) under the following conditions: 3 min at 94
 
8
 
C; 32
cycles of 45 s at 94
 
8
 
C, 90 s at 65
 
8
 
C, and 150 s at 72
 
8
 
C; and 10
min at 72
 
8
 
C. PCR primers spanning the D
 
b
 
-J
 
b region were used
as published (37). Populations that appeared to have clonal or oli-
goclonal Db-Jb rearrangement were further analyzed by the
above method for Vb usage. Primers located within each of the
Vb regions and the reverse Jb primers were used as published
(37). Ethidium bromide–stained PCR products were run on a 1%
agarose gel and visualized under ultraviolet light. To verify that
single Vb-Jb bands were indeed indicative of a single TCR,
PCR products were cloned and at least four different clones from
each product sequenced. In all cases, identical sequences were
obtained from such Vb-Jb products.
Statistical Analysis. Experimental groups were compared by
the Student’s t test with P , 0.05 considered significant.
Results
Generation of Transgenic Mice that Overexpress an Efficiently
Translated and Secreted IL-15 Mature Protein. Previous re-
ports have identified major posttranscriptional regulatory
mechanisms that control human IL-15 translation and se-
cretion (5, 22, 23). We constructed a modified murine IL-
15 cDNA that lacked the three primary posttranscriptional
checkpoints controlling wild-type IL-15, thereby optimiz-
ing for IL-15 overexpression (Fig. 1). Modifications to the
cDNA included removing upstream AUGs that impeded
translation, replacing the inefficiently translated and se-
creted endogenous IL-15 signal peptides with the IL-2 sig-
nal peptide, and stabilizing the COOH terminus of the ma-
ture protein with a FLAG epitope tag. Near global
overexpression of this modified IL-15 cDNA was driven222 Fatal Leukemia Follows Lymphocyte Expansion in IL-15 Transgenic Mice
by the MHC class I Dd promoter (30), and the 39 portion
of the hGH gene was spliced downstream and out of frame
to maximize transcription, translation, and processing of
the transgene in vivo (29). Transfection of COS-7 cells
with an expression plasmid containing the modified IL-15
cDNA resulted in secretion of bioactive murine IL-15 pro-
tein (data not shown), confirming that these modifications
resulted in efficient IL-15 protein translation and secretion.
Transgenic mice were created by microinjection of the
IL-15 transgene into pronuclear stage FVB/N embryos.
Three IL-15tg lines were identified by Southern blot analy-
sis of genomic DNA with a hGH cDNA probe (Fig. 2 a).
Although all three IL-15tg lines demonstrate a similar phe-
notype, the severity varied based upon transgene expression
at the transcript level. Here, we report the phenotype of
one representative IL-15tg line (3304 in Fig. 2 a). IL-15tg
mice developed normally as neonates, but grossly mani-
fested progressive alopecia beginning at 5–6 wk of age (see
below). The transgene transcript, now efficiently translated
and secreted, was quantified and found to be abundantly
expressed in multiple tissues from IL-15tg mice (Fig. 2 b),
in a similar pattern as the endogenous IL-15 transcript (2)
that is poorly translated and secreted. The transgenic pro-
tein was detected by immunoblot analysis of the FLAG
epitope and was present in multiple tissues (Fig. 2 c). In ad-
dition, IL-15tg mice had measurable serum levels of murine
IL-15 (Fig. 2 d). IL-15 protein was detected (mean 6 SEM,
186.7 6 41.8 pg/ml) in the serum of 9 of 12 IL-15tg mice
tested. In all (n 5 9) wild-type, nontransgenic mice, IL-15
protein was undetectable using this ELISA. Thus, IL-15tg
mice express measurable serum levels of IL-15 protein at
6–20 wk of age, whereas wild-type mice do not.
Early Lymphocytosis in IL-15tg Mice. Previous studies
have documented a role for IL-15 in the homeostasis of sev-
eral lymphocyte subsets (1). We therefore examined the pe-
ripheral blood of IL-15tg (n 5 71) and nontransgenic litter-
mates controls (n 5 51) at 6 wk of age. The IL-15tg mice
exhibited a significant increase in leukocyte number
(31,694 6 3,267/ml blood), compared with controls (7,983 6
503/ml blood, P , 1027; Fig. 3 a). The lymphocyte counts
in IL-15tg mice (21,712 6 2,718/ml blood) were signifi-
cantly higher compared with controls (3,648 6 375/ml
blood, P , 1028), demonstrating that the lymphocytosis in
the IL-15tg mice was responsible for the elevated leukocyte
numbers (Fig. 3 b). Examination of peripheral blood smears
from IL-15tg mice confirmed the expansion of small and
large granular lymphocytes (Fig. 3, c and d). This lympho-
cytosis was observed in IL-15tg mice as early as 3 wk of age.
Figure 1. Structure of the IL-15 transgene.
Three primary posttranscriptional checkpoints
were eliminated: 59 AUGs, the inefficient IL-15
signal peptide, and a COOH terminus reten-
tion sequence. Near global overexpression was
achieved by the MHC class I promoter, effi-
cient translation and secretion by use of the
IL-2 signal peptide, and stabilization of COOH
terminus by the addition of the FLAG epitope.
The 39 portion of the hGH gene is fused out of
frame for straightforward identification of the
transgene by Southern blot and to optimize
transgene expression in vivo.
Figure 2. Detection and expression of the IL-15 transgene. (a) Three FVB/N IL-15tg lines positive by Southern blot analysis with hGH gene probe
(3284, 3285, 3304), while negative line (3286) is shown for comparison. Triangle denotes the expected 2.6-kb size of the SstI digested transgene. (b) Real
time RT-PCR of tissues from a representative IL-15tg mouse. Results show the mean 6 SEM of triplicate measurements of IL-15 transgene expression
from total cellular RNA, isolated from IL-15tg tissues. Sm. Int., small intestine; Lg. Int., large intestine; Sk. Musc., skeletal muscle; BM, bone marrow.
(c) Immunoblot analysis of splenocyte lysates for transgenic protein with the FLAG epitope tag. Equal amounts of total cellular protein were loaded as
follows: lane 1, spleen cells from nontransgenic wild-type FVB mouse; and lanes 2–4, spleen cells from three different IL-15tg mice. (d) IL-15 protein
levels in IL-15tg mice. Serum from IL-15tg mice and nontransgenic wild-type controls were analyzed using a specific murine IL-15 ELISA (see Materials
and Methods).223 Fehniger et al.
Figure 3. Early lymphocytosis in IL-15tg mice. (a and b) Total white
blood cell (WBC) and lymphocyte counts in IL-15tg (n 5 71) and non-
transgenic littermate control (n 5 51) at 6 wk of age. Graphs show the
mean 6 SEM, with a significant increase in both the absolute white blood
cell (*, P , 1027) and lymphocyte counts (**, P , 1028) in IL-15tg mice.
(c and d) Representative photomicrographs at low (403) and high (1003)
magnification of peripheral blood smears from a 6-wk-old IL-15tg mouse
(IL-15tg) and a nontransgenic littermate control (WT Control). Note ex-
pansion of large granular lymphocytes in IL-15tg mouse smear.
blood of IL-15tg mice revealed that the major population
of expanded lymphocytes was DX51CD32 NK cells (Fig.
4 a). In IL-15tg mice, both the percentage (46 6 1.5% vs.
4 6 0.2%, P , 10212) and absolute number (10,161 6
1,220/ml blood vs. 142 6 15/ml blood, P , 10-11) of NK
Early Expansion in NK Cell Number and Function in IL-
15tg Mice. IL-15, acting through the IL-15R complex,
has a requisite role in NK cell lineage development (11,
12), and provision of exogenous IL-15 expands murine NK
cells in vivo (12, 38). Immunophenotyping the peripheral224 Fatal Leukemia Follows Lymphocyte Expansion in IL-15 Transgenic Mice
cells were consistently and significantly increased, com-
pared with nontransgenic littermate controls (Fig. 4 b).
Further, those DX51CD32 cells coexpressed the Ly49D
NK receptor at a frequency comparable to wild-type NK
cells (Fig. 4 a).
To confirm the expanded DX51CD32 lymphocytes
were functionally NK cells, we examined the natural cyto-
toxicity of fresh peripheral blood leukocytes from IL-15tg
mice and non-transgenic controls for their ability to lyse
YAC-1 target cells. Leukocytes from IL-15tg mice effi-
ciently lysed YAC-1 targets at relatively low effector/target
cell ratios (Fig. 4 c), consistent with the increased percent-
age of NK cells in IL-15tg mice. Of note, fresh leukocytes
from IL-15tg mice were able to efficiently lyse YAC-1 tu-
mor targets without additional in vivo or in vitro activa-
tion. As a further indicator of NK cell function, leukocytes
from IL-15tg mice were tested for their ability to secrete
IFN-g after monokine costimulation. Abundant IFN-g
protein was measured after 48 h incubation of IL-15tg lym-
phocytes in IL-12 plus IL-15 (data not shown), similar to
that reported for mature NK cells (15). Thus, at 6 wk of
age, the peripheral blood of IL-15tg mice contains a major
population of functional DX51CD32Ly491/2 NK cells.
Early Expansion of Memory Phenotype CD81 T Cells in IL-
15tg Mice. IL-15 has also been shown to be critical for
memory phenotype CD81 T cell expansion and/or sur-
vival in mice (11–13, 39). Analysis of the T cell compart-
ment revealed that the percentage of TCR-b1CD31 cells
present in the peripheral blood of IL-15tg mice was re-
duced, due to the NK cell expansion (Fig. 5 a). However,
the normal ratio of CD4/CD8 T cells (3.26 6 0.1) in non-
transgenic controls was dramatically inverted within IL-
Figure 4. Early expansions in NK cell number and function within IL-
15tg mice. (a) Flow cytometric analysis of peripheral blood lymphocytes
from representative IL-15tg and nontransgenic littermate wild-type con-
trols (WT). NK cells are DX51CD32Ly491/2, whereas T cells are
CD31DX52Ly49D2. (b) IL-15tg mice (n 5 71) have a significant in-
crease in the absolute NK cell number, compared with nontransgenic lit-
termate controls (n 5 51; *, P , 10211). Data shown are the mean 6
SEM. (c) Cytotoxicity of fresh leukocytes isolated from IL-15tg or non-
transgenic wild-type littermate controls (WT) against YAC-1 tumor tar-
gets, without any additional in vitro or in vivo activation. Data shown are
the mean 6 SEM of triplicate wells from three representative IL-15tg and
two wild-type control mice.
Figure 5. Early expansion of CD81 T cells within IL-15tg mice. (a)
Flow cytometric analysis of peripheral blood lymphocytes from represen-
tative IL-15tg and nontransgenic littermate wild-type controls (WT).
Most lymphocytes in wild-type mice are CD31TCR-b1 T cells, and the
percentage of this population is reduced in IL-15tg mice due to dilution
by the expanded NK cells. The CD4/CD8 ratio is significantly inverted
in IL-15tg mice. (b) The absolute number of CD41 T cells is identical in
IL-15tg and control mice. (c) The absolute number of CD81 T cells is
significantly increased in IL-15tg (P  , 1024), compared with control
mice. This increase in CD81 T cells is responsible for the CD4/CD8 ra-
tio. For b and c, data represent the mean CD4 or CD8 counts 6 SEM of
IL-15tg (n 6 71) and control (n 5 51) mice.225 Fehniger et al.
Figure 6. Memory phenotype of expanded CD81 T
cells. Flow cytometric analysis of peripheral blood lympho-
cytes from a representative IL-15tg mouse at 6 wk of age,
demonstrating the CD44hiLy6C1CD692CD62Llo pheno-
type, with a nontransgenic littermate control shown for
comparison. Similar results were obtained in all IL-15tg
mice examined (n 5 10). WT, wild-type.
Figure 7. IL-15tg mice develop fatal lymphocytic leukemia with age. (a) Flow cytometric analyses of peripheral blood lymphocytes isolated from rep-
resentative IL-15tg mice immediately before death. Although the DX51CD32 NK cell expansion persisted, the major lymphocyte population is
CD31TCR-b1DX5hi/lo/neg T cells. Results shown are from three different IL-15tg mice with isotype control staining shown above the DX5 and CD3
stained cells for each IL-15tg leukemia. (b) Similar lymphocyte expansions are evident in multiple lymphoid tissues from leukemic IL-15tg mice (blood,
spleen, bone marrow), as illustrated by a representative IL-15tg mouse. Tissues from a nontransgenic littermate control are shown for comparison. WT,
wild-type. (c) Leukemic IL-15tg mice have gross splenomegaly, as evidenced by increased spleen to body weight ratio. Graph shows the mean spleen/
body weight ratio 6 SEM of 22 leukemic IL-15tg mice. (d) Photomicrographs (1003) illustrating the morphology of the leukemic lymphocytes from
peripheral blood smears of four representative IL-15tg mice.226 Fatal Leukemia Follows Lymphocyte Expansion in IL-15 Transgenic Mice
15tg mice (0.59 6 0.04, P , 10232). This inversion was
due to an expansion of CD81 T cells (10-fold, P , 1024),
as the absolute number of CD41 T cells was identical be-
tween IL-15tg and nontransgenic littermate controls (Fig.
5, b and c). Further phenotypic analysis of these CD81 T
cells showed that they are CD44hiCD62LloCD692Ly6Chi,
consistent with a memory phenotype (Fig. 6).
IL-15tg Mice Develop Fatal Lymphocytic Leukemia with
Age. Between 12 and 30 wk of age, most IL-15tg mice
develop a cluster of signs including decreased activity,
weight loss, and difficulty breathing. These signs progress
for 3–7 d when the mice become acutely moribund and are
killed (average 19.6 6 1.1 wk of age). In evaluable IL-15tg
mice, a massive elevation in peripheral blood leukocyte
number, consisting mainly of lymphocytes, was observed
(mean 186,582 6 32,433/ul blood, range 47,000–
606,000/ul blood, n 5 22). Immunophenotyping revealed
that although DX51CD32 NK cells remained elevated, the
major lymphocyte population was consistently CD31
TCR-b1DX5hi/lo/neg T cells. Representative flow cy-
tometric analyses of the blood from several IL-15tg mice
that developed such massive lymphocyte outgrowth are
shown in Fig. 7 a. The expanded CD31 T cells and NK
cells were observed in multiple lymphoid tissues, including
blood, spleen, and bone marrow (Fig. 7 b). Flow cytomet-
ric analyses of expanded lymphocyte populations isolated
from 22 different IL-15tg mice revealed a consistent
phenotype of CD31TCR-b1CD21CD51CD441CD81/2
DX5hi/lo/neg. In two additional cases, CD32TCR-
b2CD82CD42DX51 lymphocyte populations were ex-
panded, likely representing a murine NK cell leukemia
(data not shown), and in no case was CD4 expression ob-
served. Concurrently, these mice demonstrated massive
splenomegaly (Fig. 7 c) with grossly enlarged livers. Analy-
sis of peripheral blood smears confirmed the dramatic lym-
phocyte expansion, some of which had striking blast-like
morphological features and prominent nucleoli (Fig. 7 d).
We next examined expanded populations of CD31
TCR-b1 lymphocytes from IL-15tg mice for clonality of
the TCR-b locus. The analyses were performed by DNA
PCR with primers that amplify all possible rearrangements
of the Jb1 and Jb2 loci followed by another DNA PCR as-
say that amplifies all possible Vb-Jb rearrangements (37).
An example of a clonal TCR-b1 T cell population isolated
from a mouse that developed fatal lymphocytic leukemia is
shown in Fig. 8 a. Amplification of the Jb2 region demon-
strated that a single J segment (Jb2.7) was used by these
lymphocytes (Fig. 8 b). After identifying the Jb clonal pop-
ulation, PCR amplification of all possible V-Jb2 rearrange-
ments identified the rearranged Vb present (Vb16) in the
genomic DNA (Fig. 8 c). Through such experiments, ex-
panded lymphocytes from 9 of 19 (48%) IL-15tg mice were
determined to be clonal, consistent with leukemia. Impor-
Figure 8. Clonal TCR-b T cell ex-
pansion in IL-15tg mice. (a) Schematic
of an example rearranged TCR-b gene
that was observed in an IL-15tg mouse
that died of fatal lymphocytic leukemia.
(b) DNA PCR gel showing a mono-
clonal Jb2.7 usage in the expanded lym-
phocytes from an IL-15tg mouse (tg), compared with polyclonal control
(C). (c) DNA PCR gel showing a monoclonal Vb16-Db2-Jb2.7 usage in
the expanded lymphocytes from an IL-15tg mouse. A faint band is visible
with the prominently used Vb4, and is present on most gels examining the
FVB/N TCR-b. (d) Example of a clonal TCR Vb61 T cell population in
a different IL-15tg mouse with fatal leukemia by flow cytometry. Blood
cells were gated on CD31 lymphocytes and assessed for expression of the
Vb6 TCR.
Figure 9. Progressive alopecia in IL-15tg mice. Photograph of a repre-
sentative 18-wk-old IL-15tg mouse, illustrating the progressive alopecia
that involves 50–90% of the skin surface area. The alopecia typically begins
at 4–6 wk of age initially involving the head and proximal limbs. A sex-
and age-matched wild-type FVB mouse is shown below for comparison.227 Fehniger et al.
tantly, mice from two independent IL-15tg lines developed
clonal lymphocytic leukemia, suggesting that this pheno-
type was not due to the location of the transgene insertion.
As further evidence of TCR-b clonality, the amplified Vb-
D-Jb products from a subset of the leukemias (n 5 4), were
cloned and sequenced. Each of these leukemias had a dis-
tinct TCR Vb usage and 100% of clones contained identi-
cal TCR-b rearrangements at the DNA level (n 5 4/4 leu-
kemias, data not shown). Flow cytometric studies on TCR
Vb expression also provided evidence that the lymphocyte
expansions were clonal (Fig. 8 d).
Progressive Alopecia and Multiorgan Lymphocytic Infiltrate of
IL-15tg Mice. Animals with dramatically elevated lym-
phocyte counts were killed for pathologic analysis. All IL-
15tg mice were remarkable for whole body alopecia (Fig.
9), splenomegaly, and lymphadenopathy. Microscopic ex-
amination of tissues harvested from these animals showed
diffuse lymphocytic infiltrates, most prominent in the peri-
toneum and surrounding intraabdominal organs. In addi-
tion, all showed marked skin involvement and expansion of
splenic white pulp. Effacement of normal architecture by
this infiltrate was seen in enlarged lymph nodes. Prominent
Figure 10. Multiorgan lymphocytic infil-
tration in IL-15tg mice. Histology sections
of skin (a–c), lung (d–f), and liver (g–i)
stained with hematoxylin and eosin. Low
power (103) micrographs contrast wild-
type (a, d, and g) and IL-15tg (b, e, and h)
tissues. High power (403) micrographs
demonstrate the lymphocytic morphology
of the infiltrating cells in the IL-15tg mice
(c, f, and i). See Results for detailed descrip-
tion of the pathology.228 Fatal Leukemia Follows Lymphocyte Expansion in IL-15 Transgenic Mice
lung and liver infiltrates were seen in most animals with
highly elevated lymphocyte counts.
Fig. 10 illustrates the skin, lung, and liver pathology
found in IL-15tg mice. Skin infiltrates were dense within
the dermis with individual lymphoid cells present within
the epidermis (Fig. 10, b and c). Also remarkable was the
presence of mast cells within the dermal infiltrate. Multiple
skin ulcerations were evident, and acute inflammatory cells
were present at these foci. In immunohistochemical studies
on frozen tissue, the invading lymphocytes were CD3 pos-
itive (data not shown), whereas no mouse NK cell marker
is available for use on tissue sections. The pattern of cuta-
neous involvement found in these animals is very similar to
that seen in patients with NK/T cell lymphomas (40).
Other skin changes consistent with long-term inflamma-
tion include epidermal hyperplasia, hyperkeratosis, and loss
of adnexal structures (e.g., hair follicles).
A spectrum of lung involvement was observed. In the
least affected mice, dense lymphoid infiltrates were identi-
fied around blood vessels. In more affected animals, lung
involvement was diffuse, involving the walls of alveolar
spaces. Fig. 10, d and e, are photomicrographs, taken at
103 and 403 magnification, of a lung section from a trans-
genic animal. Lymphoid cells are seen surrounding a lym-
phatic channel, itself containing large lymphocytes as well
as marked interstitial involvement. Fig. 10, h and i, demon-
strate the common pattern of hepatic disease, with perivas-
cular infiltrates and sinusoidal involvement.
Discussion
IL-15 is a pleiotropic cytokine important in lymphocyte
homeostasis and unusual in its tight posttranscriptional con-
trol (1). Here, we report the phenotype of transgenic mice
engineered to efficiently translate and secrete murine IL-
15, which is normally abundant as transcript in multiple
tissues but poorly translated and secreted. IL-15tg mice ex-
hibit peripheral blood lymphocytosis, with significant ex-
pansions in both the NK cell and memory phenotype
CD81 TCR-a/b T cell compartments early in life. These
results demonstrate that IL-15 is a growth factor for these
cell types in vivo, and are consistent with gene targeting
studies demonstrating that IL-15Ra2/2 and IL-152/2 mice
lack NK cells and are severely deficient in memory/acti-
vated phenotype CD81 T cells (11, 12). Similarly, mice
that lack inducible IL-15 gene expression due to disruption
of the IFN regulatory factor (IRF)-1 gene (9, 10), or are
deficient in other IL-15R components (41, 42), exhibit
NK cell and CD81 T cell defects. Continual translation
and secretion of the proinflammatory cytokine in the IL-
15tg mice over several months eventually led to the mani-
festation of T-NK lymphocytic leukemia in a significant
fraction of mice.
The exogenous provision of high doses of rhIL-15 to
wild-type or IL-152/2 mice for 1 wk results in transient
NK cell increases (12, 38). IL-15 has been shown to drive
NK cell differentiation from human (7, 43) and murine
(44) IL-2/15Rb1 NK cell precursors in the bone marrow,
as well as support mature NK cell survival in the absence of
serum or other factors (8). This suggests that multiple
mechanisms, including increased differentiation and pro-
longed survival in the periphery, are likely responsible for
the accumulation of NK cells observed in IL-15tg mice. It
also supports the notion that IL-15 may provide a physio-
logic set point that normally regulates the total number of
NK cells present in vivo. We have shown previously that
IL-15 augments NK cell function (6), and consistent with
this, fresh NK cells from IL-15tg mice exhibit potent cy-
tolytic activity against YAC-1 tumor target cells.
Similarly, exogenous provision of rhIL-15 to mice for 1
wk increases memory/activated-phenotype CD81 T cell
numbers (12, 13). Previous studies have suggested an im-
portant role for IL-15 in the antigen-independent mainte-
nance of the memory CD8 T cell pool (12, 13, 39, 45).
The consistent increase in CD81CD44hiLy6C1 T cells
within IL-15tg mice supports a role for IL-15 as one ho-
meostatic control for this population. Definitive evidence
that IL-15 maintains memory phenotype CD81 T cells
would require adoptive transfer experiments into IL-152/2
and wild-type mice. In IL-15tg mice, housed within spe-
cific pathogen-free environments, it is unclear what anti-
gens are driving the CD81CD44hi T cell expansion. We
speculate that these expansions could represent an exagger-
ated response to normally encountered nonpathogenic an-
tigens in the specific pathogen-free environment. An ex-
pansion of benign CD81 T cell clones has been observed
in normal, aged mice and humans (46). These CD81 T cell
clones expand slowly in vivo, do not bear markers of acti-
vation, do not cause malignancies, and may potentially
arise in response to chronic stimulation with a viral or au-
toantigen. The early, benign expansion of CD81CD44hi T
cells in IL-15tg mice may somehow be related to such
cells. However, the latter are initially polyclonal, whereas
the subsequent malignant clonal expansion of lymphocytes
in the IL-15tg mice is heterogeneous with regard to CD8
and even CD3 expression, i.e., TCR-a/b1CD81, TCR-
a/b1CD82, or TCR-a/b2DX51. Nonetheless, the po-
tential role of IL-15 in the clonal expansion of benign
CD81 T cells seen in elderly mice and humans warrants
investigation.
Nishimura et al. recently described transgenic mice that
globally overexpress the endogenous long signal peptide
form of IL-15, and also observed an increase in functional
CD81CD44hi T cells in lymph nodes and spleen (45), yet
there was no NK cell expansion or leukemia reported. A
recent report of transgenic mice expressing a chimeric hIL-
4R/mIL-15R on T cells suggests that there are unique
properties of CD81CD44hi T cells, in addition to high IL-
2/15Rb expression, that allows them to selectively prolif-
erate in response to IL-15 signals (47). It is interesting that
IL-15 appears to control the level of both NK and memory
phenotype CD81 T cells as both of these effectors act co-
ordinately for the clearance of many intracellular pathogens
(48, 49). Collectively, these data point toward potential
clinical utility for time-limited provision of low amounts of
IL-15 in the expansion of immune effector cells in immu-229 Fehniger et al.
nodeficient patients, or as an adjuvant to boost cellular im-
mune responses after vaccination.
IL-15tg mice develop dramatic and fatal lymphocyte ele-
vations after several months of chronic proinflammatory
cytokine stimulation. Clinical findings such as weight loss,
reduced activity, and respiratory distress, occur immedi-
ately before premature death. In a subset of these mice we
have documented that the extraordinary lymphocyte eleva-
tion is comprised of a clonal population which, with their
clinical course and histopathology, is consistent with the
development of leukemia. However, in the remainder of
IL-15tg mice that lack clonal lymphocyte expansion yet are
otherwise characterized by an identical clinical course,
other processes such as autoimmune reactions may contrib-
ute to the observed polyclonal lymphocyte expansions and
multiorgan infiltration.
The striking leukemic manifestation of this disease sug-
gests that the malignant cell is likely derived from blood or
bone marrow, as opposed to a peripheral lymphoid tissues.
The chronic proliferation and/or extended survival of lym-
phocytes in IL-15tg mice likely contribute to the accumu-
lation of additional transforming mutations, as has been
postulated for other cancers (24). In support of this, IL-15
has been shown to costimulate stem cell proliferation (7),
and extend the survival of normal NK cells (8) and T cells
(50) by preventing apoptosis. Studies to sequentially ana-
lyze these cells for such secondary genetic alterations are
underway, with the hope of providing new insights into
the pathogenesis of lymphocytic leukemia.
IL-15 was originally identified as a 4-a helix bundle cy-
tokine with similar in vitro biological properties as IL-2,
consistent with their shared receptor components (IL-2/
15Rbgc; reference 2). Interestingly, Ishida and et al. gener-
ated mice that globally overexpress recombinant IL-2
driven by a MHC class I promoter (51). These IL-2 trans-
genic mice develop a mild lymphocytic skin infiltrate com-
posed of T cells, but do not demonstrate excessive lym-
phocyte expansions or malignant transformation such as
leukemia. To our knowledge, IL-15tg mice are unique
among cytokine transgenics in their induction of leukemia.
Collectively, these data strongly support existing data that
show little in vivo redundancy when comparing the roles
of IL-2 and IL-15 in health and disease.
The chronic lymphocytosis and subsequent leukemia ob-
served in IL-15tg mice share some clinical features and
manifestations with the human disease large granular lym-
phocytic (LGL) leukemia (28). These include extra-lym-
phoid involvement, a chronic course evolving to an acute
expansion, and the prevalence of T cell subtypes. Further,
the histopathology of the lymphocytic infiltrates in IL-15tg
mice resembles those observed in NK-T lymphomas (40,
52). Lymphocytes isolated from patients with LGL leuke-
mia express all three components of the IL-15R complex
(abg), and increased IL-15 expression was noted in mac-
rophages from these patients (53). In addition, early in vitro
propagation of LGL leukemia cell lines can be maintained
in the presence of IL-15. We are currently investigating
whether increased IL-15 protein expression in the bone
marrow or other tissues of LGL leukemia patients may con-
tribute to the initiation or pathophysiology of this disease.
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